Gamma-linolenic acid induces apoptosis in B-chronic lymphocytic leukaemia cells in vitro.

Leuk Lymphoma

University Department of Haematology, School of Clinical, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

Published: January 2001

AI Article Synopsis

Article Abstract

Gamma linolenic acid (GLA) is cytotoxic to many types of human cancer cells. Most chemotherapeutic agents are cytotoxic by inducing apoptosis. We examined the apoptotic activity of GLA on purified B-cells isolated from patients with B-cell chronic lymphocytic leukaemia (B-CLL) and from normal individuals. GLA significantly increased the degree of apoptosis in B-CLL B-cells after 24 hours of culture. The mean percentage of cells undergoing apoptosis when cultured in medium alone (spontaneous apoptosis) was 20% (range: 7 to 31%) (n=25) and in the presence of GLA (5 microg-60 microg) was: 42%-95%. In the presence of GLA 5 microg/ml and dexamethasone the degree of apoptosis was 86% (range: 72 to 100%). GLA induced apoptosis in B-CLL B-cells at a higher level than that observed with normal B-cells at all lower concentrations tested 5, 10 and 15 microg/ml: P=0.045; 0.027 and 0.022, respectively. At 30 microg/ml of GLA, no significant difference in the percentage of cells displaying apoptosis between B-CLL and normal B-cells was observed (P=0.075). GLA induced apoptosis in B-CLL T-cells at both 10 and 30 microg/ml. The degree of apoptosis in normal T-cells with GLA was also significant at the higher concentration of 30 microg/ml. Interleukin 4 (IL4), a viability factor in B-CLL, and vitamin E, an anti-oxidant, protected B-CLL B-cells against GLA (20 microg/ml)-induced apoptosis. These results demonstrate that GLA induces apoptosis in B-CLL B- and T-cells cells in vitro and that they are more susceptible to GLA-induced apoptosis than normal peripheral blood B- and T-cells.

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428190109057939DOI Listing

Publication Analysis

Top Keywords

apoptosis b-cll
20
apoptosis
13
degree apoptosis
12
b-cll b-cells
12
gla
11
induces apoptosis
8
lymphocytic leukaemia
8
cells vitro
8
b-cll
8
b-cll normal
8

Similar Publications

Article Synopsis
  • The BAG3 protein plays a key role in regulating cell survival and is being studied as a potential target for treating various cancers, particularly B-cell chronic lymphocytic leukemia (B-CLL).
  • Research shows that silencing BAG3 in stromal fibroblasts leads to increased apoptosis in B-CLL cells by disrupting critical survival signaling pathways.
  • The study highlights the link between BAG3 expression, cytokine networks, and tumor survival, suggesting that understanding these interactions could lead to new therapies for CLL.
View Article and Find Full Text PDF

Background: High expression of the glycosyltransferase UGT2B17 represents an independent adverse prognostic marker in chronic lymphocytic leukemia (CLL). It also constitutes a predictive marker for therapeutic response and a drug resistance mechanism. The key determinants driving expression of the UGT2B17 gene in normal and leukemic B-cells remain undefined.

View Article and Find Full Text PDF

Orai1 channel capacity to control store-operated Ca entry (SOCE) and B-cell functions is poorly understood and more specifically in B-cell cancers, including human lymphoma and leukemia. As compared to normal B-cells, Orai1 is overexpressed in B-chronic lymphocytic leukemia (B-CLL) and contributes in resting B-CLL to mediate an elevated basal Ca level through a constitutive Ca entry, and in BCR-activated B-cell to regulate the Ca signaling response. Such observations were confirmed in human B-cell lymphoma and leukemia lines, including RAMOS, JOK-1, MEC-1 and JVM-3 cells.

View Article and Find Full Text PDF

Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies.

Asian J Pharm Sci

May 2022

Institute of Immunology, and Department of Orthopedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Although chimeric antigen receptor-modified (CAR) T cell therapy has been successfully applied in the treatment of acute B lymphocytic leukemia, its effect on Burkitt lymphoma (BL) and chronic B lymphocytic leukemia (B-CLL) is unsatisfactory. Moreover, fatal side effects greatly impede CAR T cell application. Extracellular vesicles (EVs) are excellent carriers of therapeutic agents.

View Article and Find Full Text PDF

The 1,4,7-tris-(2-pyridinylmethyl)-1,4,7-triazacyclononane ligand () and its bifunctional analogue were synthesized to investigate their action toward zinc(II) depletion related to the apoptosis phenomenon in chronic lymphocytic leukemia (CLL) cells. was used as the "free" ligand, while its "graftable" derivative was conjugated on a newly synthesized bifunctional sialoglycan, , selected to specifically bind CD22 biomarker expressed on the B-CLL cell surface. Both compounds were produced with good yields thanks to a Sonogashira coupling reaction and an orthoester function, respectively, for the chelator and the targeting moiety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!